Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Itzel Bustos-Villalobos"'
Autor:
Patricia Angela Sibal, Shigeru Matsumura, Toru Ichinose, Itzel Bustos‐Villalobos, Daishi Morimoto, Ibrahim R. Eissa, Mohamed Abdelmoneim, Mona Alhussein Mostafa Aboalela, Nobuaki Mukoyama, Maki Tanaka, Yoshinori Naoe, Hideki Kasuya
Publikováno v:
Molecular Oncology, Vol 18, Iss 5, Pp 1259-1277 (2024)
Oncolytic viruses (OVs) can selectively replicate in tumor cells and remodel the microenvironment of immunologically cold tumors, making them a promising strategy to evoke antitumor immunity. Similarly, agonists of the stimulator of interferon genes
Externí odkaz:
https://doaj.org/article/c189155387224a828e2869d71171198a
Autor:
Mohamed Abdelmoneim, Ibrahim Ragab Eissa, Mona Alhussein Aboalela, Yoshinori Naoe, Shigeru Matsumura, Patricia Angela Sibal, Itzel Bustos-Villalobos, Maki Tanaka, Yasuhiro Kodera, Hideki Kasuya
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-15 (2022)
Abstract Oncolytic virus (OV) therapy is a promising cancer immunotherapy, especially for cold tumors by inducing the direct lysis of cancer cells and initiation of potent antitumor response. Canerpaturev (C-REV) is an attenuated oncolytic herpes sim
Externí odkaz:
https://doaj.org/article/c1af3202992a44e695757064bacf6038
Autor:
Mohamed Abdelmoneim, Mona Alhussein Aboalela, Yoshinori Naoe, Shigeru Matsumura, Ibrahim Ragab Eissa, Itzel Bustos-Villalobos, Patricia Angela Sibal, Yuhei Takido, Yasuhiro Kodera, Hideki Kasuya
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 17, p 13353 (2023)
The tumor microenvironment (TME) plays a pivotal role in the fate of cancer cells, and tumor-infiltrating immune cells have emerged as key players in shaping this complex milieu. Cancer is one of the leading causes of death in the world. The most com
Externí odkaz:
https://doaj.org/article/a241089eb76e4242bc7a83d61c46e5cc
Autor:
Daishi Morimoto, Shigeru Matsumura, Itzel Bustos-Villalobos, Patricia Angela Sibal, Toru Ichinose, Yoshinori Naoe, Ibrahim Ragab Eissa, Mohamed Abdelmoneim, Nobuaki Mukoyama, Noriyuki Miyajima, Maki Tanaka, Yasuhiro Kodera, Hideki Kasuya
Publikováno v:
Cells, Vol 10, Iss 6, p 1502 (2021)
Oncolytic virus (OV) therapy is widely considered as a major breakthrough in anti-cancer treatments. In our previous study, the efficacy and safety of using C-REV for anti-cancer therapy in patients during stage I clinical trial was reported. The sti
Externí odkaz:
https://doaj.org/article/dd38fa8a2e174e95a0014579daa73dc1
Autor:
Ibrahim Ragab Eissa, Yoshinori Naoe, Itzel Bustos-Villalobos, Toru Ichinose, Maki Tanaka, Wu Zhiwen, Nobuaki Mukoyama, Taishi Morimoto, Noriyuki Miyajima, Hasegawa Hitoki, Seiji Sumigama, Branko Aleksic, Yasuhiro Kodera, Hideki Kasuya
Publikováno v:
Frontiers in Oncology, Vol 7 (2017)
Oncolytic viruses (OVs) are opening new possibilities in cancer therapy with their unique mechanism of selective replication within tumor cells and triggering of antitumor immune responses. HF10 is an oncolytic herpes simplex virus-1 with a unique ge
Externí odkaz:
https://doaj.org/article/dfaa583e56c8449589481c0b863f5f2b
Autor:
Junko Iwatsuki, Hideki Kasuya, Nobutaro Ban, Norbert Skokauskas, Hideki Takami, Tetsuya Yagi, Takeshi Kondo, Noriyuki Takahashi, Branko Aleksic, Hiroshi Nishigori, Itzel Bustos-Villalobos
Publikováno v:
Advances in Medical Education and Practice
Junko Iwatsuki,1,2 Takeshi Kondo,3 Noriyuki Takahashi,3â 5 Hideki Takami,3 Hiroshi Nishigori,6 Itzel Bustos-Villalobos,7 Branko Aleksic,7,8 Hideki Kasuya,7 Nobutaro Ban,9 Tetsuya Yagi,10 Norbert Skokauskas11,12 1International Collaboration Plann
Autor:
Shigeru Matsumura, Yasushi Fujimoto, Toru Ichinose, Yoshinori Naoe, Maki Tanaka, Yasuhiro Kodera, Michihiko Sone, Daishi Morimoto, Itzel Bustos-Villalobos, Hideki Kasuya, Noriyuki Miyajima, Ibrahim Ragab Eissa, Nobuaki Mukoyama, Mohamed Abdelmoneim
Publikováno v:
International Journal of Cancer. 149:214-227
Oncolytic viruses (OVs) remodel the tumor microenvironment by switching a "cold" tumor into a "hot" tumor with high CD8+ T-cell infiltration. CD8+ T-cell activity plays an essential role in the antitumor efficacy of OVs. However, the activity of T ce
Autor:
Ibrahim Ragab, Eissa, Nobuaki, Mukoyama, Mohamed, Abdelmoneim, Yoshinori, Naoe, Shigeru, Matsumura, Itzel, Bustos-Villalobos, Toru, Ichinose, Noriyuki, Miyajima, Daishi, Morimoto, Maki, Tanaka, Yasushi, Fujimoto, Michihiko, Sone, Yasuhiro, Kodera, Hideki, Kasuya
Publikováno v:
International journal of cancerREFERENCES. 149(1)
Oncolytic viruses (OVs) remodel the tumor microenvironment by switching a "cold" tumor into a "hot" tumor with high CD8
Autor:
Yoshiki Hirooka, Yoshinori Naoe, Takuya Ishikawa, Hidemi Goto, Yasuhiro Kodera, Itzel Bustos Villalobos, Maki Tanaka, Hideki Kasuya, Nobuto Koyama, Toru Ichinose, Hiroki Kawashima, Eizaburo Ohno
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Cancer
BMC Cancer
Background Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy trea
Autor:
Yoshinori Naoe, Yusuke Koide, Nobuaki Mukoyama, Zhiwen Wu, Shigeru Matsumura, Daishi Morimoto, Yoko Nishikawa, Noriyuki Miyajima, Toru Ichinose, Itzel Bustos Villalobos, Maki Tanaka, Ibrahim Ragab Eissa, Hideki Kasuya, Suguru Yamada, Yasuhiro Kodera
Publikováno v:
Molecular Therapy: Oncolytics, Vol 13, Iss, Pp 107-115 (2019)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
The naturally occurring oncolytic herpes simplex virus canerpaturev (C-REV), formerly HF10, proved its therapeutic efficacy and safety in multiple clinical trials against melanoma, pancreatic, breast, and head and neck cancers. Meanwhile, patients wi